Literature DB >> 8901748

Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease).

S Makita1, M Nakamura, H Murakami, K Komoda, K Kawazoe, K Hiramori.   

Abstract

BACKGROUND: Thromboangiitis obliterans (TAO) is an occlusive arterial disease and a separate disease entity from atherosclerosis. It occurs mainly in the small and medium-sized vessels. Although the cause of TAO is unknown, systemic factors (immunological or humoral) may be involved in addition to abnormal peripheral microcirculation. Endothelium is now recognized as an important factor in the maintenance of microvascular circulation and the inhibition of platelet aggregation. This study examines the possible impairment of endothelium-dependent vasodilation in the peripheral vasculature of patients with TAO. METHODS AND
RESULTS: Forearm blood flow (FBF) changes induced by the endothelium-dependent vasodilator acetylcholine, the endothelium-independent vasodilator sodium nitroprusside, and occlusion-induced reactive hyperemia were measured plethysmographically in eight patients with TAO and in eight healthy control subjects matched for age and smoking status. The increase in FBF response to intra-arterial acetylcholine infusion was lower in patients with TAO than in healthy control subjects (peak FBF, 22.9 +/- 2.9 versus 14.1 +/- 2.8 mL/min per dL of tissue volume; P < .01). In contrast, there was no significant difference in the increase in FBF response to sodium nitroprusside infusion between the two groups (peak FBF 13.1 +/- 4.0 versus 16.3 +/- 2.5 mL/min per dL of tissue volume; P = NS). In the case of reactive hyperemia, there were no significant differences between the two groups at any time points of hyperemia (peak FBF, 32.9 +/- 4.0 versus 31.4 +/- 3.3 mL/min per dL of tissue volume; P = NS).
CONCLUSIONS: These results indicate that peripheral endothelium-dependent vasodilation is impaired in the nondiseased limb of patients with TAO. This type of vascular dysfunction may contribute to such characteristics as segmental proliferative lesion and thrombus formation in the peripheral vessels of patients with TAO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901748

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Thromboangiitis Obliterans (Buerger's Disease).

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

2.  Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.

Authors:  Joaquin De Haro; Aurora Florez; Jose Luis Fernandez; Francisco Acin
Journal:  BMJ Case Rep       Date:  2009-05-12

3.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

4.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 5.  Conditions presenting with symptoms of peripheral arterial disease.

Authors:  Aditya M Sharma; Patrick T Norton; Daisy Zhu
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

6.  Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.

Authors:  Joaquin De Haro; Francisco Acin; Silvia Bleda; Cesar Varela; Leticia Esparza
Journal:  BMC Cardiovasc Disord       Date:  2012-02-14       Impact factor: 2.298

Review 7.  Cytokines and adhesion molecules in the pathogenesis of vasculitis.

Authors:  J S Sundy; B F Haynes
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

8.  Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients.

Authors:  R Dellalibera-Joviliano; E E Joviliano; J S Silva; P R B Evora
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

9.  The Wound Healing Effects of Iloprost in Patients with Buerger's Disease: Claudication and Prevention of Major Amputations.

Authors:  A Afsharfard; M Mozaffar; F Malekpour; A Beigiboroojeni; M Rezaee
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

10.  Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study.

Authors:  Annie M Bérard; Aurélie Bedel; Rémi Le Trequesser; Geneviève Freyburger; Alan Nurden; Sylvie Colomer; Viviane Guérin; Marie-Christine Vergnes; François Becker; Gabriel Camelot; Luc Bressolette; Philippe Lacroix; Jean-Pierre Cambou; Alessandra Bura-Rivière; Joseph Emmerich; Michel Darmon; Anne-Marie Deletraz; Samir Mesli; Brigitte Colombies; Virginie Vanbrugghe; Claude Conri; Joël Constans
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.